Literature DB >> 15605181

Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates.

E Roilides1, E Farmaki, J Evdoridou, J Dotis, E Hatziioannidis, M Tsivitanidou, E Bibashi, I Filioti, D Sofianou, C Gil-Lamaignere, F-M Mueller, G Kremenopoulos.   

Abstract

A prospective observational study of invasive candidiasis was conducted in the neonatal intensive care unit of Aristotle University in Hippokration Hospital between 1994 and 2000. During this period, 59 neonates developed invasive candidiasis (58 cases of candidemia and 1 case of peritonitis), resulting in an overall incidence of 1.28% that showed a decreasing trend over the study period. Eleven (18.6%) cases developed within the first week of life and the others within a mean (+/-SEM) of 13.4+/-1.7 days after birth. The three most frequent causative species were Candida albicans (65.5%), Candida parapsilosis (15.5%), and Candida tropicalis (7%). C. albicans was the predominant species between 1994 and 1998, whereas, non-albicans Candida spp., particularly C. parapsilosis, were the most frequent species during the period 1999-2000 (P<0.001). While the overall mortality due to candidemia was 29% (17 of 59 cases), mortality associated with C. albicans and C. parapsilosis was 39.5% and 11.1%, respectively (P=0.032), and that observed in the 1999-2000 period was 0% (P=0.011). Virtually all isolates were susceptible to amphotericin B, flucytosine, fluconazole, and itraconazole, and no increases in minimal inhibitory concentrations were observed during these years. With the exception of a limited cluster of cases due to genotypically identical isolates, no clonal relation of C. albicans isolates was found. Moreover, no clonal persistence of C. albicans and no decrease in antifungal drug susceptibility occurred over the 6-year study period. Non-albicans Candida spp., mostly C. parapsilosis, have emerged as important pathogens in neonatal intensive care units, with infected patients having better outcomes as compared to patients infected with C. albicans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605181     DOI: 10.1007/s10096-004-1210-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  45 in total

1.  Candida isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility.

Authors:  J L Rowen; J M Tate; N Nordoff; L Passarell; M R McGinnis
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

Review 2.  Neonatal candidosis: clinical picture, management controversies and consensus, and new therapeutic options.

Authors:  Eugene Leibovitz
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

3.  Vertical and horizontal transmission of unique Candida species to premature newborns.

Authors:  L A Waggoner-Fountain; M W Walker; R J Hollis; M A Pfaller; J E Ferguson; R P Wenzel; L G Donowitz
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

4.  Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers.

Authors:  J J Weems; M E Chamberland; J Ward; M Willy; A A Padhye; S L Solomon
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

5.  Cluster of Candida parapsilosis primary bloodstream infection in a neonatal intensive care unit.

Authors:  C L da Silva; R M dos Santos; A L Colombo
Journal:  Braz J Infect Dis       Date:  2001-02       Impact factor: 1.949

Review 6.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors:  V Krcmery; A J Barnes
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

7.  Candida parapsilosis bloodstream infections in neonatal intensive care unit patients: epidemiologic and laboratory confirmation of a common source outbreak.

Authors:  S F Welbel; M M McNeil; R J Kuykendall; T J Lott; A Pramanik; R Silberman; A D Oberle; L A Bland; S Aguero; M Arduino; S Crow; W R Jarvis
Journal:  Pediatr Infect Dis J       Date:  1996-11       Impact factor: 2.129

Review 8.  Candidemia in a pediatric population.

Authors:  J K Stamos; A H Rowley
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

9.  Management of neonatal candidiasis. Neonatal Candidiasis Study Group.

Authors:  J L Rowen; J M Tate
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

Review 10.  Candida infections in the neonate.

Authors:  Rachel L Chapman
Journal:  Curr Opin Pediatr       Date:  2003-02       Impact factor: 2.856

View more
  34 in total

1.  Neonatal intensive care unit candidemia: epidemiology, risk factors, outcome, and critical review of published case series.

Authors:  A Spiliopoulou; G Dimitriou; E Jelastopulu; I Giannakopoulos; E D Anastassiou; Myrto Christofidou
Journal:  Mycopathologia       Date:  2011-11-11       Impact factor: 2.574

2.  Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility.

Authors:  Maiken Cavling Arendrup; Kurt Fuursted; Bente Gahrn-Hansen; Irene Møller Jensen; Jenny Dahl Knudsen; Bettina Lundgren; Henrik C Schønheyder; Michael Tvede
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

3.  Neonatal candidiasis: epidemiology, risk factors, and clinical judgment.

Authors:  Daniel K Benjamin; Barbara J Stoll; Marie G Gantz; Michele C Walsh; Pablo J Sánchez; Abhik Das; Seetha Shankaran; Rosemary D Higgins; Kathy J Auten; Nancy A Miller; Thomas J Walsh; Abbot R Laptook; Waldemar A Carlo; Kathleen A Kennedy; Neil N Finer; Shahnaz Duara; Kurt Schibler; Rachel L Chapman; Krisa P Van Meurs; Ivan D Frantz; Dale L Phelps; Brenda B Poindexter; Edward F Bell; T Michael O'Shea; Kristi L Watterberg; Ronald N Goldberg
Journal:  Pediatrics       Date:  2010-09-27       Impact factor: 7.124

4.  Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.

Authors:  Maria Siopi; Aikaterini Tarpatzi; Eleni Kalogeropoulou; Sofia Damianidou; Alexandra Vasilakopoulou; Sophia Vourli; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

5.  The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia.

Authors:  Jack D Sobel
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

6.  Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells.

Authors:  Athanasios Chatzimoschou; Aspasia Katragkou; Maria Simitsopoulou; Charalampos Antachopoulos; Elpiniki Georgiadou; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

7.  Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies.

Authors:  Eveline C van Asbeck; Yhu-Chering Huang; Angela N Markham; Karl V Clemons; David A Stevens
Journal:  Mycopathologia       Date:  2007-09-15       Impact factor: 2.574

8.  Outbreak of Candida parapsilosis in a neonatal intensive care unit: a health care workers source.

Authors:  Rigoberto Hernández-Castro; Sara Arroyo-Escalante; Erika M Carrillo-Casas; David Moncada-Barrón; Elizabeth Alvarez-Verona; Lorena Hernández-Delgado; Patricia Torres-Narváez; Antonio Lavalle-Villalobos
Journal:  Eur J Pediatr       Date:  2009-12-04       Impact factor: 3.183

Review 9.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

Review 10.  Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis.

Authors:  Mohan Pammi; Linda Holland; Geraldine Butler; Attila Gacser; Joseph M Bliss
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.